stockrow
Saturday 7 November 2026
Export ACET’s income statement to Excel — free account
Adicet Bio, Inc.
ACET Healthcare Biotechnology
Adicet Bio, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $25.0 million.
- EPS
- +63.4%
- Free cash flow
- +24.9%
Quarter to June 2026, against a year earlier
3.05
0.13
+4.45%
Follow ACET
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (78.08%) | (72.19%) | (67.55%) | (71.73%) |
+8 more TTM periods Free account |
|
| (63.62%) | (60.35%) | (56.62%) | (59.52%) | ||
ROIC |
(2,518.16%) | (2,135.23%) | (5,773.17%) | (1,133.54%) | |
Return on Tangible Assets |
(84.75%) | (79.47%) | (74.91%) | (108.97%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(7.91) | (8.53) | (14.07) | (17.63) | |
Free Cash Flow |
(84.97) | (91.62) | (96.98) | (100.36) | |
Capital Expenditures |
(0.44) | (0.28) | (1.74) | (1.92) | |
| Other line items | |||||
Cash ROIC |
(35.56%) | (32.90%) | (30.46%) | (47.15%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(1,280.35) | (1,896.65) | (3,213.53) | (7,560.69) | |
Operating CF/Net income |
0.85 | 0.84 | 0.82 | 0.86 | |
Depreciation/Fixed assets |
0.16 | 0.16 | 0.14 | 0.13 | |
Capex/Depreciation |
(0.19) | (0.12) | (0.75) | (0.84) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(7.87) | (8.50) | (13.82) | (17.29) | |
Capex per Share |
(0.04) | (0.03) | (0.25) | (0.34) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates